Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
NCT06904482Phase 2Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2025
- Primary completion
- Feb 2027
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Haplo-cord HCT in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 3 years. Started Aug 2025; status: recruiting.
02
Drugs
Haplo-cord HCT
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT06904482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904482.